Mast cell activation and autism

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 1, 2012, Pages 34-41

  Theoharides, Theoharis C ^a,b   Angelidou, Asimenia ^a,b   Alysandratos, Konstantinos Dionysios ^a,b   Zhang, Bodi ^a   Asadi, Shahrzad ^a   Francis, Konstantinos ^b   Toniato, Elena ^c   Kalogeromitros, Dimitrios ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Chieti Medical Center   (Italy)

Author keywords

Allergy; Autism; Brain; Inflammation; Mast cells; Stress

Indexed keywords

BRAIN PROTEIN; CORTICOTROPIN RELEASING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOCHONDRIAL DNA; TUMOR NECROSIS FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGIC DISEASE; AUTISM; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELLULAR IMMUNITY; CHILD HEALTH; CHRONIC URTICARIA; FOOD ALLERGY; HUMAN; IMMUNE DYSREGULATION; IMMUNOAFFINITY CHROMATOGRAPHY; MAST CELL; MASTOCYTOSIS; NATURAL KILLER CELL; PATHOGENESIS; PERINATAL STRESS; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PREMATURE LABOR; PREMATURITY; PRENATAL STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANXIETY; BLOOD-BRAIN BARRIER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CROSS-SECTIONAL STUDIES; HUMANS; HYPERSENSITIVITY; INFLAMMATION; MAST CELLS; PREVALENCE; STRESS, PSYCHOLOGICAL;

EID: 82955245468     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.017     Document Type: Review

References (113)

1. Johnson C.P., Myers S.M. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007, 120:1183-1215.
2. Matson J.L., Kozlowski A.M. Autistic regression. Res Autism Spectr Disord 2010, 4:340-345.
3. Zappella M. Autistic regression with and without EEG abnormalities followed by favourable outcome. Brain Dev 2010, 32:739-745.
4. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009, 65:591-598.
5. Kogan M.D., Blumberg S.J., Schieve L.A., Boyle C.A., Perrin J.M., Ghandour R.M., Singh G.K., Strickland B.B., Trevathan E., van Dyck P.C. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009, 5:1395-1403.
6. Levy S.E., Mandell D.S., Schultz R.T. Autism. Lancet 2009, 374:1627-1638.
7. Weiss L.A., Arking D.E., Daly M.J., Chakravarti A. A genome-wide linkage and association scan reveals novel loci for autism. Nature 2009, 461:802-808.
8. Herbert M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23:103-110.
9. Palmieri L., Persico A.M. Mitochondrial dysfunction in autism spectrum disorders: Cause or effect?. Biochim Biophys Acta 2010, 1797:1130-1137.
10. Warren R.P., Yonk L.J., Burger R.A., Cole P., Odell J.D., Warren W.L., White E., Singh V.K. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest 1990, 19:245-251.
11. Vojdani A., Mumper E., Granpeesheh D., Mielke L., Traver D., Bock K., Hirani K., Neubrander J., Woeller K.N., O'Hara N., Usman A., Schneider C., Hebroni F., Berookhim J., McCandless J. Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15. J Neuroimmunol 2008, 205:148-154.
12. Enstrom A.M., Lit L., Onore C.E., Gregg J.P., Hansen R., Pessah I.N., Hertz-Picciotto I., Van de Water J.A., Sharp F.R., Ashwood P. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2009, 23:124-133.
13. Jyonouchi H., Sun S., Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001, 120:170-179.
14. Singh V.K. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 1996, 66:143-145.
15. Sweeten T.L., Posey D.J., Shankar S., McDougle C.J. High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol Psychiatry 2004, 55:434-437.
16. Li X., Chauhan A., Sheikh A.M., Patil S., Chauhan V., Li X.M., Ji L., Brown T., Malik M. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009, 207:111-116.
17. Zimmerman A.W., Jyonouchi H., Comi A.M., Connors S.L., Milstien S., Varsou A., Heyes M.P. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005, 33:195-201.
18. Chez M.G., Dowling T., Patel P.B., Khanna P., Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007, 36:361-365.
19. Croonenberghs J., Bosmans E., Deboutte D., Kenis G., Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002, 45:1-6.
20. Grigorenko E.L., Han S.S., Yrigollen C.M., Leng L., Mizue Y., Anderson G.M., Mulder E.J., de Bildt A., Minderaa R.B., Volkmar F.R., Chang J.T., Bucala R. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008, 122:e438-e445.
21. Angelidou A., Francis K., Vasiadi M., Alysandratos K.-D., Zhang B., Theoharides A., Lykouras L., Kalogeromitros D., Theoharides T.C. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation 2010, 7:48.
22. Evers B.M., Bold R.J., Ehrenfried J.A., Li J., Townsend C.M., Klimpel G.R. Characterization of functional neurotensin receptors on human lymphocytes. Surgery 1994, 116:134-139.
23. Ramez M., Bagot M., Nikolova M., Boumsell L., Vita N., Chalon P., Caput D., Ferrara P., Bensussan A. Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes. J Invest Dermatol 2001, 117:687-693.
24. Lemaire I. Neurotensin enhances IL-1 production by activated alveolar macrophages. J Immunol 1988, 140:2983-2988.
25. Carraway R., Cochrane D.E., Lansman J.B., Leeman S.E., Paterson B.M., Welch H.J. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol 1982, 323:403-414.
26. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Jelliffe L.L., Hansen R.L., Phillips T.M. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001, 49:597-606.
27. Nelson P.G., Kuddo T., Song E.Y., Dambrosia J.M., Kohler S., Satyanarayana G., Vandunk C., Grether J.K., Nelson K.B. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 2006, 24:73-80.
28. Ross D.L., Klykylo W.M., Hitzemann R. Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr Neurol 1987, 3:83-86.
29. Zhang B., Angelidou A., Alysandratos K.D., Vasiadi M., Francis K., Asadi S., Theoharides A., Sideri k., Lykouras L., Kalogeromitros D., Theoharides T.C. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J Neuroinflammation 2010, 7:80.
30. Saresella M., Marventano I., Guerini F.R., Mancuso R., Ceresa L., Zanzottera M., Rusconi B., Maggioni E., Tinelli C., Clerici M. An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children. Biol Psychiatry 2009, 66:978-984.
31. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80:1-15.
32. Goines P., Van de Water J. The immune system's role in the biology of autism. Curr Opin Neurol 2010, 23:111-117.
33. Theoharides T.C., Kempuraj D., Redwood L. Autism: an emerging 'neuroimmune disorder' in search of therapy. Exp Opin Pharmacotherapy 2009, 10:2127-2143.
34. Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Expert Rev Clin Immunol 2010, 6:397-411.
35. Kilic G., Guler N., Suleyman A., Tamay Z. Chronic urticaria and autoimmunity in children. Pediatr Allergy Immunol 2010, 21:837-842.
36. Croen L.A., Grether J.K., Yoshida C.K., Odouli R., Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005, 159:151-157.
37. Magalhaes E.S., Pinto-Mariz F., Bastos-Pinto S., Pontes A.T., Prado E.A., Deazevedo L.C. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009, 216:108-112.
38. Gurney J.G., McPheeters M.L., Davis M.M. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006, 160:825-830.
39. Sacco R., Curatolo P., Manzi B., Militerni R., Bravaccio C., Frolli A., Lenti C., Saccani M., Elia M., Reichelt K.L., Pascucci T., Puglisi-Allegra S., Persico A.M. Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Res 2010, 3:237-252.
40. Bakkaloglu B., Anlar B., Anlar F.Y., Oktem F., Pehlivanturk B., Unal F., Ozbesler C., Gokler B. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008, 12:476-479.
41. Enstrom A., Krakowiak P., Onore C., Pessah I.N., Hertz-Picciotto I., Hansen R.L., Van de Water J.A., Ashwood P. Increased IgG4 levels in children with autism disorder. Brain Behav Immun 2008.
42. Tomicic S., Norrman G., Falth-Magnusson K., Jenmalm M.C., Devenney I., Bottcher M.F. High levels of IgG4 antibodies to foods during infancy are associated with tolerance to corresponding foods later in life. Pediatr Allergy Immunol 2009, 20:35-41.
43. Jyonouchi H., Geng L., Cushing-Ruby A., Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation 2008, 5:52.
44. Theoharides T.C. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol 2009, 22:859-865.
45. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26:465-485.
46. Akin C., Valent P., Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006, 6:282-288.
47. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., Marone G., Nunez R., Akin C., Sotlar K., Sperr W.R., Wolff K., Brunning R.D., Parwaresch R.M., Austen K.F., Lennert K., Metcalfe D.D., Vardiman J.W., Bennett J.M. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
48. Theoharides T.C., Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 2006, 1088:78-99.
49. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005, 23:749-786.
50. Theoharides T.C., Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12.
51. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55:241-269.
52. Rozniecki J.J., Dimitriadou V., Lambracht-Hall M., Pang X., Theoharides T.C. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res 1999, 849:1-15.
53. Farhadi A., Fields J.Z., Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol 2007, 13:3027-3030.
54. Levy S.E., Souders M.C., Ittenbach R.F., Giarelli E., Mulberg A.E., Pinto-Martin J.A. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry 2007, 61:492-497.
55. Buie T., Campbell D.B., Fuchs G.J., Furuta G.T., Levy J., Vandewater J., Whitaker A.H., Atkins D., Bauman M.L., Beaudet A.L., Carr E.G., Gershon M.D., Hyman S.L., Jirapinyo P., Jyonouchi H., Kooros K., Kushak R., Levitt P., Levy S.E., Lewis J.D., Murray K.F., Natowicz M.R., Sabra A., Wershil B.K., Weston S.C., Zeltzer L., Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010, 125(Suppl 1):S1-S18.
56. Varadaradjalou S., Feger F., Thieblemont N., Hamouda N.B., Pleau J.M., Dy M., Arock M. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003, 33:899-906.
57. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
58. Conti P., Pang X., Boucher W., Letourneau R., Reale M., Barbacane R.C., Thibault J., Theoharides T.C. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997, 89:4120-4127.
59. Ashwood P., Enstrom A., Krakowiak P., Hertz-Picciotto I., Hansen R.L., Croen L.A., Ozonoff S., Pessah I.N., de Water J.V. Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008, 204:149-153.
60. Gebhardt T., Lorentz A., Detmer F., Trautwein C., Bektas H., Manns M.P., Bischoff S.C. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005, 54:928-934.
61. Kulka M., Alexopoulou L., Flavell R.A., Metcalfe D.D. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004, 114:174-182.
62. Dunn S.J., Greenberg H.B., Ward R.L., Nakagomi O., Burns J.W., Vo P.T., Pax K.A., Das M., Gowda K., Rao C.D. Serotypic and genotypic characterization of human serotype 10 rotaviruses from asymptomatic neonates. J Clin Microbiol 1993, 31:165-169.
63. Grandjean P., Landrigan P.J. Developmental neurotoxicity of industrial chemicals. Lancet 2006, 368:2167-2178.
64. Hertz-Picciotto I., Park H.Y., Dostal M., Kocan A., Trnovec T., Sram R. Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development. Basic Clin Pharmacol Toxicol 2008, 102:146-154.
65. Young H.A., Geier D.A., Geier M.R. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110-118.
66. Kwon O., Lee E., Moon T.C., Jung H., Lin C.X., Nam K.S., Baek S.H., Min H.K., Chang H.W. Expression of cyclooxygenase-2 and pro-inflammatory cytokines induced by 2, 2', 4, 4', 5, 5'-hexachlorobiphenyl (PCB 153) in human mast cells requires NF-kappa B activation. Biol Pharm Bull 2002, 25:1165-1168.
67. Kempuraj D., Asadi S., Zhang B., Manola A., Hogan J., Peterson E., Theoharides T.C. Mercury induces inflammatory mediator release from human mast cells. J Neuroinflammation 2010, 7:20.
68. Theoharides T.C., Kempuraj D., Tagen M., Conti P., Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007, 217:65-78.
69. Cao J., Papadopoulou N., Kempuraj D., Boucher W.S., Sugimoto K., Cetrulo C.L., Theoharides T.C. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005, 174:7665-7675.
70. Theoharides T.C., Doyle R., Francis K., Conti P., Kalogeromitros D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008, 29:375-382.
71. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332:1351-1362.
72. Slominski A., Wortsman J., Pisarchik A., Zbytek B., Linton E.A., Mazurkiewicz J.E., Wei E.T. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J 2001, 15:1678-1693.
73. Donelan J., Boucher W., Papadopoulou N., Lytinas M., Papaliodis D., Theoharides T.C. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006, 103:7759-7764.
74. Gillott A., Standen P.J. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil 2007, 11:359-370.
75. Makrigiannakis A., Semmler M., Briese V., Eckerle H., Minas V., Mylonas I., Friese K., Jeschke U. Maternal serum corticotropin-releasing hormone and ACTH levels as predictive markers of premature labor. Int J Gynaecol Obstet 2007, 97:115-119.
76. Grammatopoulos D.K. Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma. J Neuroendocrinol 2008, 20:432-438.
77. Limperopoulos C., Bassan H., Sullivan N.R., Soul J.S., Robertson R.L., Moore M., Ringer S.A., Volpe J.J., du Plessis A.J. Positive screening for autism in ex-preterm infants: prevalence and risk factors. Pediatrics 2008, 121:758-765.
78. Kinney D.K., Munir K.M., Crowley D.J., Miller A.M. Prenatal stress and risk for autism. Neurosci Biobehav Rev 2008, 32:1519-1532.
79. Kuban K.C., O'Shea T.M., Allred E.N., Tager-Flusberg H., Goldstein D.J., Leviton A. Positive screening on the Modified Checklist for Autism in Toddlers (M-CHAT) in extremely low gestational age newborns. J Pediatr 2009, 154:535-540.
80. Soderholm J.D., Yates D.A., Gareau M.G., Yang P.C., MacQueen G., Perdue M.H. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol 2002, 283:G1257-G1263.
81. Chandler N., Jacobson S., Connolly R., Esposito P., Theoharides T.C. Acute stress shortens the time of onset of experimental allergic encephalomyelitis (EAE) in SJL/J mice. Brain Behav Immun 2002, 16:757-763.
82. Teunis M.A., Heijnen C.J., Sluyter F., Bakker J.M., Van Dam A.M., Hof M., Cools A.R., Kavelaars A. Maternal deprivation of rat pups increases clinical symptoms of experimental autoimmune encephalomyelitis at adult age. J Neuroimmunol 2002, 133:30-38.
83. Vojdani A., Campbell A.W., Anyanwu E., Kashanian A., Bock K., Vojdani E. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002, 129:168-177.
84. Wills S., Cabanlit M., Bennett J., Ashwood P., Amaral D.G., Van de Water J. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun 2008, 23:64-74.
85. Singer H.S., Morris C.M., Williams P.N., Yoon D.Y., Hong J.J., Zimmerman A.W. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006, 178:149-155.
86. Cabanlit M., Wills S., Goines P., Ashwood P., Van de Water J. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann NY Acad Sci 2007, 1107:92-103.
87. Theoharides T.C., Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007, 12:1615-1628.
88. Wallon C., Yang P., Keita A.V., Ericson A.C., McKay D.M., Sherman P.M., Perdue M.H., Soderholm J.D. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008, 57:50-58.
89. Forbes E.E., Groschwitz K., Abonia J.P., Brandt E.B., Cohen E., Blanchard C., Ahrens R., Seidu L., McKenzie A., Strait R., Finkelman F.D., Foster P.S., Matthaei K.I., Rothenberg M.E., Hogan S.P. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008, 205:897-913.
90. Dommergues M.A., Patkai J., Renauld J.C., Evrard P., Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann Neurol 2000, 47:54-63.
91. Abbott N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000, 20:131-147.
92. Stone L.A., Smith M.E., Albert P.S., Bash C.N., Maloni H., Frank J.A., McFarland H.F. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology 1995, 45:1122-1126.
93. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003, 9:540-549.
94. Soon D., Altmann D.R., Fernando K.T., Giovannoni G., Barkhof F., Polman C.H., O'Connor P., Gray B., Panzara M., Miller D.H. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol 2007, 254:306-314.
95. Harwood M., nielewska-Nikiel B., Borzelleca J.F., Flamm G.W., Williams G.M., Lines T.C.,. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007, 45:2179-2205.
96. Kumar A., Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008, 11:469-473.
97. Haleagrahara N., Radhakrishnan A., Lee N., Kumar P. Flavonoid quercetin protects against swimming stress-induced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol 2009, 621:46-52.
98. Parker-Athill E., Luo D., Bailey A., Giunta B., Tian J., Shytle R.D., Murphy T., Legradi G., Tan J. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009, 217:20-27.
99. Jang S., Kelley K.W., Johnson R.W. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A 2008, 105:7534-7539.
100. Dirscherl K., Karlstetter M., Ebert S., Kraus D., Hlawatsch J., Walczak Y., Moehle C., Fuchshofer R., Langmann T. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010, 7:3.
101. Sternberg Z., Chadha K., Lieberman A., Drake A., Hojnacki D., Weinstock-Guttman B., Munschauer F. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. J Neuroinflammation 2009, 6:28.
102. Jang S.W., Liu X., Yepes M., Shepherd K.R., Miller G.W., Liu Y., Wilson W.D., Xiao G., Blanchi B., Sun Y.E., Ye K. A selective TrkB agonist with potent neurotrophic activities by 7, 8-dihydroxyflavone. Proc Natl Acad Sci USA 2010, 107:2687-2692.
103. Theoharides T.C. Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflammation 2009, 6:29.
104. Hollman P.C., Katan M.B. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 1997, 51:305-310.
105. Hollman P.C., de Vries J.H., van Leeuwen S.D., Mengelers M.J., Katan M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers, Am.J. Clin Nutr 1995, 62:1276-1282.
106. McDonald M.E., Paul J.F. Timing of increased autistic disorder cumulative incidence. Environ Sci Technol 2010, 44:2112-2118.
107. Blaxill M.F. What's going on? The question of time trends in autism. Public Health Rep 2004, 119:536-551.
108. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I.N., Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 2010, 126:1099-1104.
109. Conti P., Pang X., Boucher W., Letourneau R., Reale M., Barbacane R.C., Thibault J., Theoharides T.C. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997, 89:4120-4127.
110. Castellani M.L., De Lutiis M.A., Toniato E., Conti F., Felaco P., Fulcheri M., Theoharides T.C., Caraffa A., Antinolfi P., Conti P., Cuccurullo C., Ciampoli C., Felaco M., Orso C., Salini V., Cerulli G., Kempuraj D., Tete S., Shaik B. Impact of RANTES, MCP-1 and IL-8 in mast cells. J Biol Regul Homeost Agents 2010, 24:1-6.
111. Humbles A.A., Lu B., Friend D.S., Okinaga S., Lora J., Al-Garawi A., Martin T.R., Gerard N.P., Gerard C. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002, 99:1479-1484.
112. Commins S.P., Satinover S.M., Hosen J., Mozena J., Borish L., Lewis B.D., Woodfolk J.A., Platts-Mills T.A. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009, 123:426-433.
113. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126:1099-1104.